US cancer drugs shortage crisis drives temporary drug importation, quick approval and draft guidance
This article was originally published in SRA
The US Food and Drug Administration has taken steps to address the shortage of critically needed cancer drugs by allowing for the temporary importation into the US of one product that the agency has not yet approved and by speeding up its review and approval of another product1.
You may also be interested in...
How FDA, health care providers, and Pfizer and other drug makers are responding to a shortage of emergency medicines from the fragile, overstressed US sterile injectables sector.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.